Recruitment of Matrix Metalloproteinase-9 (MMP-9) to the Fibroblast Cell Surface by Lysyl Hydroxylase 3 (LH3) Triggers Transforming Growth Factor-β (TGF-β) Activation and Fibroblast Differentiation*

Cynthia Dayer and Ivan Stamenkovic
From the Division of Experimental Pathology, Institute of Pathology, CHUV, Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 25, Lausanne CH1011, Switzerland

Received for publication, October 28, 2014, and in revised form, March 30, 2015. Published, JBC Papers in Press, March 30, 2015. DOI 10.1074/jbc.M114.622274

Solid tumor growth triggers a wound healing response. Similar to wound healing, fibroblasts in the tumor stroma differentiate into myofibroblasts (also referred to as cancer-associated fibroblasts) primarily, but not exclusively, in response to transforming growth factor-β (TGF-β). Myofibroblasts in turn enhance tumor progression by remodeling the stroma. Among proteases implicated in stroma remodeling, matrix metalloproteinases (MMPs), including MMP-9, play a prominent role. Recent evidence indicates that MMP-9 recruitment to the tumor cell surface enhances tumor growth and invasion. In the present work, we addressed the potential relevance of MMP-9 recruitment to and activity at the surface of fibroblasts. We show that recruitment of MMP-9 to the fibroblast cell surface occurs through its fibronectin-like (FN) domain and that the molecule responsible for the recruitment is lysyl hydroxylase 3 (LH3). Functional assays suggest that both pro- and active MMP-9 trigger α-smooth muscle actin expression in cultured fibroblasts, reflecting myofibroblast differentiation, possibly as a result of TGF-β activation. Moreover, the recombinant FN domain inhibited both MMP-9-induced TGF-β activation and α-smooth muscle actin expression by displacing MMP-9 from the fibroblast cell surface. Together our results uncover LH3 as a new docking receptor of MMP-9 on the fibroblast cell surface and demonstrate that the MMP-9 FN domain is essential for the interaction. They also show that the recombinant FN domain inhibits MMP-9-induced TGF-β activation and fibroblast differentiation, providing a potentially attractive therapeutic reagent toward attenuating tumor progression where MMP-9 activity is strongly implicated.

Tumor cell interactions with host tissue stroma play a key role in determining tumor progression that culminates in metastatic growth. It is well established that malignant tumor growth initiates a wound healing response that maintains a state of tissue remodeling, which favors tumor survival, invasion, and dissemination. Orchestration of tumor-associated tissue remodeling is mediated in part by tumor cells and in part by a variety of recruited host tissue cells, including various leukocyte subsets and mesenchymal cell subtypes ranging from mesenchymal stem cells to myofibroblasts (1–3). Most of these cells participate in generating soluble mediators that include a plethora of cytokines, chemokines, growth factors, and enzymes. Among the proteolytic enzymes implicated in tumor-host cross-talk are matrix metalloproteinases (MMPs), a large family of zinc-dependent extracellular matrix (ECM)-degrading endopeptidases that play a key role in tissue remodeling during development and repair (4). The majority of MMPs are secreted, but at least a fraction of their proteolytic activity is observed at the cell surface where they can be anchored by a variety of cell surface receptors to provide controlled degradation of the ECM and activation of a variety of latent growth factors (5). Whether or not cell surface anchoring of secreted MMPs occurs exclusively in autocrine fashion in the context of tissue remodeling or whether it may also occur in paracrine fashion whereby MMP-anchoring cells are distinct from MMP-secreting cells remains to be clarified.

MMP-9, also known as gelatinase B, has been shown to play a prominent role in the progression of numerous tumor types by promoting tumor cell invasion and angiogenesis (6, 7). Similar to other MMPs, MMP-9 is synthesized as an inactive zymogen, or pro-MMP-9, composed of a propeptide, a catalytic domain containing fibronectin-like (FN) repeats, a linker region or hinge domain, and a C-terminal hemopexin-like (HEX) domain thought to be necessary for substrate recognition (4). The FN

*This work was supported by Swiss National Science Foundation (FNS) Grant 310030_150024 and a grant from the Swiss Institute for Experimental Cancer Research (ISREC) Foundation.

1 To whom correspondence should be addressed. Tel: 41-21-314-7136; Fax: 41-21-314-7110; E-mail: Ivan.Stamenkovic@chuv.ch.

2 The abbreviations used are: MMP, matrix metalloproteinase; LH3, lysyl hydroxylase-3; FN, fibronectin-like; α-SMA, α-smooth muscle actin; ECM, extracellular matrix; HEX, hemopexin-like; TMLC, transformed mink lung epithelial cells; HSFT, human skin fibroblasts; NI-NTA, nickel-nitritolriacetic acid; PLA, proximity ligation assay; PLOD3, procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3.
MMP-9 Recruitment to the Cell Surface by LH3

domain, which is found only in MMP-9 and MMP-2, is composed of three tandem fibronectin type II-like motifs that form a collagen-binding domain critical for the positioning of substrates for subsequent cleavage (8). The collagen-binding domain of MMP-9 has been shown to bind gelatin (9), elastin, and both native and denatured types I, II, III, IV, and V collagen (8, 10). Each fibronectin type II-like module displays binding specialization, which generates exosites specific for other ligands degraded by the protease (10). Cooperation among collagen binding sites within these three modules increases substrate specificity and thereby has the potential to localize the enzyme to collagen either in the extracellular matrix or on the cell surface (11).

MMP-9 expression is low or absent in normal quiescent tissues but is strongly induced under conditions that trigger tissue remodeling, including development, wound healing, and tumor invasion. MMP-9 is produced by tumor-associated host tissue cells, including endothelial cells, various leukocytes, and tumor cells themselves, and is thought to promote tumor growth and metastasis (4, 6, 12–14). Several secreted MMPs, including pro-MMP-9, can at least transiently be anchored to the cell surface, which directs their proteolytic activity toward pericellular substrates and may provide protection from natural inhibitors. However, the mechanisms that underlie their association with the cell membrane appear to be diverse and remain to be fully explored (5, 15, 16). Thus far, MMP-9 has been shown to use the cell membrane in certain tumor cell types and keratinocytes among others the cell surface hyaluronan receptor CD44 as a docking molecule (17). This association stabilizes MMP-9 proteolytic activity at the cell surface to facilitate controlled collagen IV degradation and to promote invasion (17). In addition, CD44-associated MMP-9 as well as MMP-2 can cleave and activate latent TGF-β1 and -2 (18). Thus, coordination of CD44, MMP-9, and TGF-β function may provide a physiological mechanism of tissue remodeling that can be adopted by malignant cells to promote their own growth and dissemination (18, 19). As key regulators of ECM turnover, fibroblasts may include MMP-9 in their arsenal of tissue remodeling reagents. However, mechanisms that govern putative MMP-9 association with the surface of normal stromal cells, including fibroblasts, remain to be elucidated. Fibroblasts produce low amounts of MMP-9, suggesting that they may recruit tumor cell or leukocyte-derived MMP-9 to their own cell surface to promote ECM remodeling by harnessing its proteolytic activity.

In the present work, we show that MMP-9 produced by tumor cells is recruited to the fibroblast surface and that recruitment requires the FNII repeats or collagen-binding domain of MMP-9. We demonstrate that the structure that mediates MMP-9 docking to the fibroblast surface is provided by lysyl hydroxylase 3 (LH3), which displays lysyl hydroxylase as well as galactosyl- and glucosyltransferase activity (20). LH3 is expressed in the endoplasmic reticulum but is also associated with the plasma membrane via collagenous proteins (21). We show that LH3-mediated MMP-9 recruitment contributes to TGF-β activation, which stimulates fibroblast differentiation into myofibroblasts. Tumor cells and leukocytes may thus provide a source of MMP-9 that fibroblasts can recruit and use to activate TGF-β and stimulate their own differentiation.

Experimental Procedures

Cell Lines—Human embryonic kidney (HEK) 293T, fibrosarcoma (HT1080), transformed mink lung epithelial cells (TMLC), glioblastoma (U251), osteosarcoma (U2OS), breast adenocarcinoma (MDA-MB231), human skin fibroblasts (HSF), human lung embryonic fibroblasts (MRC-5), and Chinese hamster ovary (CHO) cells were cultures in DMEM supplemented with 10% fetal bovine serum.

Chemical Compounds—Chemical compounds used included: 4-aminophenylmercuric acetate (164610, Calbiochem), Complete Mini EDTA-free protease inhibitors (1183617001, Roche Applied Science), FeC⁺ blocking reagent (130-059-901, Miltenyi Biotec), FuGENE 6 Transfection Reagent (E2692, Promega), Interferin (409-01, Polyplus Transfection), Sulfo-SBEd Biotin Label Transfer Reagent (33034, Pierce), SuperSignal West Pico Chemiluminescent Substrate (34080, Thermo Scientific Pierce), human TGF-β1 (100-B-001, R&D Systems), Duolink II PLA Probe Anti-Mouse PLUS (DUO92001, Sigma-Aldrich), Duolink II PLA Probe Anti-Rabbit MINUS (DUO92005, Sigma-Aldrich), Duolink In Situ Detection Reagents Red (DUO92008, Sigma-Aldrich), and procollagen-lysine, 2-oxoglutarate 5-dioxigenase 3 (PLOD3) (human; three unique 27-mer siRNA duplexes) (SR305927, Origene).

Antibodies—Antibodies used were as follows: anti-HA-agarose matrix (11 815 016 001, Roche Applied Science), anti-LH3 (11027-1-AP, ProteinTech), anti-MMP-9 (MS-817-P0, Thermo Scientific), anti-α-SMA (A2547, Sigma), anti-tubulin (CP06, Calbiochem), anti-transferrin receptor (13-6800, Invitrogen), anti-TGF-β1,2,3 (MAB1835, R&D Systems), anti-v5 (R960-25, Invitrogen), donkey anti-mouse Alexa Fluor 488 (A21202, Invitrogen), Ni-NTA-agarose beads (30210, Qiagen), streptavidin-agarose beads (DAM1467561, Millipore), anti-v5-agarose beads (A7345, Sigma), horseradish peroxidase (HRP)-conjugated sheep anti-mouse (NA931V, GE Healthcare), and goat anti-rabbit (P0448, Dako).

Expression Constructs—Wild type (WT) pro-MMP-9 and the different MMP-9 constructs, including the catalytically dead protein containing the E402Q mutation, the FN domain composed of the fibronectin type II-like motifs (FN223–389), the hemopexin homology domain (HEX520–707), the FN domain containing the E402Q mutation, the FN domain comprising the E402Q mutant lacking the FN domain, the ΔHEX or MMP-9Δ223–389 mutant lacking the FN domain, the ΔHEX or MMP-9Δ520–707 mutant lacking the hemopexin homology domain, and CD5, were inserted into the pLIVC vector, derived from the pLVTHM lentiviral vector by the removal of the v5 tagging sequences encoding 6 histidines and the v5 peptide.

Virus Production—60% confluent HEK293T cells in a 100-mm dish were transfected with 1.25 μg of pMDD2G (envelope plasmid), 3.75 μg of pCMV5 (packaging plasmid), and 5 μg of pLIVC (transfer vector) containing MMP-9 or the different mutants using FuGENE 6 Transfection Reagent at a ratio of 1:3 and incubated at 37 °C. Lentiviruses were collected after 48 h, filtered through 0.45-μm filters, and concentrated by ultracentrifugation.

Retroviral Infection—Target cells (CHO, U2OS, HT1080, and MRC-5) at 40% confluence in 6 wells were washed with PBS.
and infected in two rounds of 8-h intervals with lentiviruses using Polybrene (1:1000) overnight at 37 °C. Cells were then washed with PBS and transferred to a 100-mm dish with fresh medium. On the following day, cells were selected with puromycin (1 µg/µl for CHO and U2OS and 2 µg/µl for MRC-5).

**His Tag Purification**—Stable transfectants of each His-tagged construct were established in U2OS and CHO cells. Purification was performed using the histidine tag and high affinity nickel beads as follows. The supernatant of CHO cells provided by Evitria (Zürich, Switzerland) was incubated with Ni-NTA-agarose beads (2 ml of beads for 1 liter of sample), which were then washed with PBS and in washing solution (5 mM imidazole, 20 mM Tris-Cl, pH 7.5, and 200 mM NaCl). Purified proteins were eluted in 20 mM and 200 mM imidazole, and fractions were concentrated with Amicon centrifugal filters (Millipore) depending on the molecular weight (50,000 nominal molecular weight limit for pro-MMP-9 and ΔFN and 3000 nominal molecular weight limit for FN). Protein concentration was determined by densitometry using ImageJ.

**Pro-MMP-9 Activation**—Activation of pro-MMP-9 was performed directly on nickel beads using 4-aminophenylmercuric acetate. 35 mg of 4-aminophenylmercuric acetate was dissolved in 10 ml of 0.1 M NaOH and diluted in TCC reaction buffer (50 mM Tris-Cl, pH 7.5, 1 mM CaCl₂, and 0.05% Triton X-100) to obtain a 2.5 mM solution. Pro-MMP-9 bound to Ni-NTA-agarose beads was incubated with this solution at 37 °C for 3 h and eluted as described before.

**Recruitment Assay**—Tumor cell lines and fibroblasts were incubated overnight at 37 °C with filtered conditioned medium from U2OS cells stably expressing recombinant MMP-9 or its different mutants or with 0.5 µg/ml purified peptides. The following day, cells were lysed using lysis buffer (10 mM Tris-Cl, pH 7.5, 150 mM NaCl, and 1% Triton X-100) containing Complete Mini EDTA-free protease inhibitors. Immunoblotting of conditioned medium and cell lysates was performed using anti-v5 antibody, and the ImageJ program was used for recruitment quantification.

**Cell Fractionation**—Cells grown in 2 × 150-mm dishes until 60–70% confluent were washed and scraped in cold PBS and centrifuged for 5 min at 300 × g at 4 °C. Membranes were sensitized by resuspending cell pellets in 1 ml of homogenization buffer (250 mM sucrose, 3 mM imidazole, and phosphatase and protease inhibitor mixtures, pH 7.4). Postnuclear supernatant was obtained by mechanical disruption of cells with a 22-gauge needle and centrifugation for 10 min at 600 × g at 4 °C. Postnuclear supernatant was subjected to ultracentrifugation for 45 min at 100,000 × g at 4 °C to separate cytosol (supernatant) from membrane (pellet) fractions. Membranes were washed twice with homogenization buffer and solubilized using lysis buffer containing Complete Mini EDTA-free protease inhibitors.

**Western Blot**—Western blotting was performed according to standard procedures. The following antibody concentrations were used: anti-v5, 1:5000; anti-transferrin receptor, 1:1000; anti-LH3, 1:500; anti-α-SMA, 1:5000; anti-tubulin, 1:4000; anti-MMP-9, 1:200; HRP-conjugated sheep anti-mouse, 1:20,000; and goat anti-rabbit, 1:20,000. ECL was revealed using SuperSignal West Pico Chemiluminescent Substrate.

**Live Immunofluorescence**—MRC-5 fibroblasts were grown on glass coverslips until they reached confluence. Cells were treated with pro-MMP-9, FN, E402Q, ΔFN, and CD5 and incubated with anti-v5 antibody (1:1500) for 1 h at 4 °C, washed with PBS, and further incubated with secondary anti-mouse Alexa Fluor 488 antibody (1:1500) for 1 h at 4 °C. Antibodies were diluted in blocking buffer (PBS and 10% FBS). Cells were then fixed with 4% paraformaldehyde for 20 min at room temperature, washed with PBS, and mounted using Immuno-Mount. DAPI (Roche Applied Science) was used to visualize the nuclei. Images were acquired with a Leica SP5 AOPS confocal microscope.

**Mass Spectrometry**—Confluent MRC-5 cells in square plates (Nunc) were treated with 50 µg of Sulfo-SBED Biotin Label Transfer Reagent-labeled MMP-9, FN, and ΔFN at 37 °C for 4 h. Cells were washed in the dark and cross-linked applying UV light at 365 nm for 8 min before lysis. Finally, cell lysates were immunoprecipitated using v5-agarose beads and subjected to mass spectrometry analysis at the Protein Analysis Facility (Lausanne, Switzerland).

**Luciferase Assay**—The luciferase assay system (E1501, Promega) was used according to the manufacturer’s instructions. Briefly, TMLC transfected with the plasminogen activator inhibitor-1 promoter responsive to TGF-β and linked to a luciferase reporter system were plated at 3 × 10⁵ cells/ml in 24 wells for 6 h. MRC-5-conditioned medium collected after 3 days was incubated with TMLC at 37 °C for 20 h. Cells were then washed with PBS and lysed with 1 × lysis buffer for 20 min on ice. 20 µl of cell lysates was mixed with 90 µl of Luciferase substrate. Luminescence was read at 570 nm using a Synergy MX luminometer for 2 s with autosensitivity.

**Immunoprecipitation**—Confluent MRC-5 cells in a 25-cm dish were treated with 13 µg of Sulfo-SBED-labeled v5-tagged MPP-9, FN, and ΔFN overnight at 37 °C. The interaction was cross-linked with UV light at 365 nm for 8 min after which MRC-5 cells were lysed with lysis buffer. 4 µg of cell lysates was precleared with HA-agarose matrix for 1 h at 4 °C and then immunoprecipitated with anti-v5-agarose beads overnight at 4 °C. Beads were washed seven times with lysis buffer and a final wash with PBS, and proteins were eluted by boiling the beads for 5 min in sample buffer. Purified complexes were analyzed by Western blotting using anti-LH3 antibody.

**LH3 Knockdown**—MRC-5 cells in 6-well plates at 30% confluence were transfected with 1 nm siRNA pool against LH3. After 48–72 h, 0.5 µg/ml purified v5-tagged MMP-9, FN, or ΔFN was incubated with control and LH3-depleted MRC-5 cells overnight at 37 °C.

**Proximity Ligation Assay (PLA)**—MRC-5 cells at 80% confluence in 6-well plates containing 8-mm coverslips were incubated with primary antibodies mouse anti-MMP-9 (1:300), rabbit anti-LH3 (1:50), and mouse anti-v5 (1:1500) for 1 h at room temperature and then fixed with 4% paraformaldehyde in PIPES buffer, pH 6.8 for 12 min at room temperature. PLA amplification was labeled with Alexa Fluor 594. Coverslips were counterstained with DAPI, mounted, and imaged using a Zeiss LSM710 confocal fluorescence microscope with a 40× oil immersion objective. The resulting images were analyzed using a script written in ImageJ macro language.
MMP-9 Recruitment to the Cell Surface by LH3

A

B

C

D
FACS—MRC-5 cells were incubated with v5-tagged MMP-9 and ΔFN overnight at 37 °C. Cells were then scraped in PBS, blocked with FcR blocking reagent (1:10 diluted in PBS) for 30 min at 4 °C, and incubated with anti-v5 or an irrelevant mouse isotype-matched antibody (1:400) for 3 h followed by anti-mouse Alexa Fluor 488-conjugated antibody (1:400) for 30 min at room temperature. DAPI was used to discriminate between living and dead cells. Cells were sorted using a Beckman Coulter Gallios flow cytometry system and analyzed using FlowJo V10.

Statistical Analysis—Graphs and statistical analysis were carried out using GraphPad Prism 6.0 software. Results represent mean values ± S.E. in all graphs. p values were as follows: ns, p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001.

Results

Pro-MMP-9 Is Recruited to the Fibroblast Cell Surface—To compare association of MMP-9 with the surface of tumor versus stromal cells, we incubated HEK293T, HT1080 (fibrosarcoma), TMLC, U251 (glioblastoma), U2OS (osteosarcoma), MDA-MB231 (breast carcinoma), and immortalized HSF and MRC-5 (human fetal lung fibroblasts) in conditioned medium of U2OS cells engineered to secrete v5-tagged pro-MMP-9. Following overnight incubation, cell membranes were isolated by cell fractionation, and protein recruitment was assessed by anti-v5 antibody blot analysis. We observed pro-MMP-9 to be more markedly recruited to fibroblast membranes (HSF and MRC-5) than to those of the different tumor cell lines (Fig. 1A). Cell fractionation analysis confirmed that pro-MMP-9 is recruited to fibroblast membranes.

The FN Domain of MMP-9 Is Necessary and Sufficient for Its Recruitment to the Fibroblast Cell Surface—Pro-MMP-9 recruitment to the cell surface has been proposed to be mediated by its HEX domain (13). However, it is possible that different MMP domains may be responsible for MMP-9 docking to the surface of different cell types. Accordingly, we asked whether the HEX or other domains of MMP-9 mediates its recruitment to the fibroblast cell surface. We therefore engineered a series of deletion mutants corresponding to defined MMP-9 domains tagged with sequences encoding 6 histidines and the v5 peptide. The mutants included a catalytically dead protein containing the E402Q mutation within the catalytic domain, ΔFN lacking the FNII repeat collagen-binding domain, ΔHEX lacking the hemopexin homology domain; FN composed of fibronectin type II-like repeats (FN223–389) only, and HEX composed of the hemopexin homology domain (HEX320–707) only (Fig. 1B). All mutants were inserted into the pLIVC retroviral vector and stably produced in CHO cells. Each mutant was compared with v5-tagged pro-MMP-9 for recruitment to fibroblasts by incubating MRC-5 cells in the corresponding CHO cell-conditioned medium overnight at 37 °C and subsequently performing Western blot analysis using antibody directed against the v5 peptide. The mutants included a catalytically dead pro-MMP-9 and ΔHEX, and E402Q were recruited to MRC-5 fibroblasts, whereas those lacking the FN domain were not (Fig. 1C). Immunofluorescence analysis using anti-v5 antibody confirmed the observation that both pro-MMP-9 and the inactive E402Q mutant are recruited to the MRC-5 cell surface. The FN domain alone was also , whereas constructs lacking the FN motifs, including ΔFN and CD5, used as a negative unrelated protein control were not (Fig. 1D). The observation that ΔHEX is less strongly detected than functional or catalytically dead MMP-9 on the fibroblast cell surface as assessed by Western blot analysis suggests that the presence of the hemopexin domain may help optimize recruitment. However, we did not observe cell surface recruitment of the HEX domain alone. To further reinforce the notion that MMP-9 binds to the cell surface via its FN domain, FACS analysis of non-permeabilized MRC-5 cells incubated with v5-tagged MMP-9 or the ΔFN mutant was performed. The results clearly indicate that MMP-9 but not the ΔFN mutant is recruited to MRC-5 cell surface membrane (Fig. 2). Together, these observations indicate that it is primarily the FN domain of MMP-9 that recognizes structures on the fibroblast cell surface.

MMP-9 Activity Promotes Latent TGF-β Activation and Induces α-SMA Expression in Resting Fibroblasts—To address the physiological significance of MMP-9 recruitment to the fibroblast cell surface, we first determined whether the active or only the precursor form of MMP-9 is recruited to the MRC-5 cell surface. Recombinant pro-MMP-9 from conditioned culture medium of stably transfected CHO cells was activated using 4-aminophenylmercuric acetate on nickel beads during the His tag purification step. Incubation of MRC-5 cells with pro-MMP-9, active MMP-9, and subsequent anti-v5 antibody blot analysis of cell lysates revealed that both pro- and active MMP-9 are recruited to the fibroblast cell surface (Fig.
A Live MRC-5 cells incubated with MMP-9

- isotype-matched antibody
- anti-v5 antibody

B Live MRC-5 cells incubated with ΔFN

- isotype-matched antibody
- anti-v5 antibody

C

- isotype-matched antibody
- ΔFN anti-v5 antibody
- MMP-9 anti-v5 antibody
This observation suggests that the proteolytically active form of MMP-9 can be retained at the cell membrane as a result of interactions mediated by its FN domain.

MMP-9 has been shown to play a prominent role in tumor growth and invasion in part by activating latent TGF-β in a functional complex with CD44 at the surface of keratinocytes and selected tumor cells (18). Hence, we asked whether the presence of cell surface-anchored pro-MMP-9 and its active form might induce TGF-β activation in MRC-5-conditioned culture medium. Accordingly, we performed a functional TGF-β assay using TMLC stably transfected with the plasminogen activator inhibitor-1 promoter, which is responsive to active TGF-β and linked to the luciferase reporter gene (22). MRC-5 fibroblasts were treated for 24 or 72 h with purified recombinant MMP-9, its different mutants, or TGF-β1 (10 ng/ml) used as a positive control. MMP-9 derivatives included pro-MMP-9, active MMP-9, the catalytically inactive E402Q mutant, and FN. The corresponding MRC-5-conditioned media were used for luciferase reporter assays in TMLC. We observed that both pro- and active MMP-9 induce TGF-β expression in cultured fibroblasts, whereas the inactive mutants E402Q and FN do not enhance baseline MRC-5-derived TGF-β activity (Fig. 3B). Moreover, 24- and 72-h exposure to recombinant MMP-9 and TGF-β resulted in roughly comparable induction of luciferase reporter expression. These observations were confirmed by immunoblotting of MRC-5 cell lysates from four independent experiments. Analysis of α-SMA expression from four independent experiments is shown. Expression quantification was normalized to tubulin (tub). Results represent mean values ± S.E. (error bars). *, p ≤ 0.05; ****, p ≤ 0.0001.
TGF-β is a potent inducer of fibroblast differentiation into myofibroblasts. We therefore addressed the possibility that MMP-9 activity at the surface of MRC-5 cells may facilitate their differentiation into myofibroblasts. Differentiation was assessed by incubating resting MRC-5 cells for 72 h with purified pro-MMP-9, active MMP-9, the catalytically inactive E402Q mutant, ΔFN, or TGF-β1 (10 ng/ml) as a positive control. Cells were then lysed, and expression of α-SMA, a reliable myofibroblast marker that is weakly expressed in MRC-5 cells, was assessed. Incubation with pro- and active MMP-9 led to an increase in α-SMA expression in cultured MRC-5 fibroblasts (Fig. 3C), whereas incubation with E402Q and ΔFN mutants failed to do so. These observations support the notion that MMP-9 activity promotes differentiation of fibroblasts into myofibroblasts.

The FN Domain Behaves as Competitive Inhibitor of MMP-9 and Decreases Both TGF-β Activation and α-SMA Expression in Resting Fibroblasts—Given that the FN domain is necessary and sufficient for MMP-9 recruitment to the fibroblast cell surface, we interrogated its ability to compete with MMP-9 for cell membrane docking and to inhibit MMP-9-induced TGF-β activation. We therefore incubated MRC-5 cells for 72 h with active MMP-9, pro-MMP-9, the FN domain only (Fig. 4A, FN), pro-MMP-9 with anti-TGF-β antibody (proMMP-9:αTGF-β), pro-MMP-9 with a 10-fold excess of the FN domain (proMMP-9:FN 1:10) that corresponds to a molar ratio of 1:34, or TGF-β1 (10 ng/ml) as a positive control and assessed the corresponding conditioned culture media for luciferase reporter induction. Whereas the FN domain alone had no effect on TGF-β activation (Fig. 4A) and displayed no catalytic activity as assessed by gelatin zymography (data not shown), a 34-fold molar excess of the FN domain in the presence of pro-MMP-9 significantly reduced TGF-β activation almost as strongly as a neutralizing anti-TGF-β antibody. Thus, exogenously added recombinant FN domain of MRC-5 cells can inhibit MMP-9 activity as measured by TGF-β activation.

We next asked whether inhibition of TGF-β activation by the FN domain could prevent α-SMA expression in resting fibroblasts, which would reflect abrogation of their differentiation into myofibroblasts. As described above, MRC-5 fibroblasts were treated for 72 h with pro-MMP-9, the FN domain only (Fig. 4B, FN), pro-MMP-9 in the presence of anti-TGF-β neutralizing antibody (proMMP-9:αTGF-β), pro-MMP-9 in the presence of an excess of the FN domain (proMMP-9:FN 1:10), or the positive control TGF-β1 (10 ng/ml). Cells remained viable after the 72-h treatment, and cell lysis was performed to assess α-SMA expression. We observed that α-SMA expression in MRC-5 treated with the FN domain alone was comparable with that in untreated MRC-5 (Fig. 4B). However, the FN domain added in 34-fold molar excess of pro-MMP-9 significantly reduced α-SMA expression even more potently so than the neutralizing anti-TGF-β antibody. The fact that MMP-9-
**MMP-9 Recruitment to the Cell Surface by LH3**

### Table: Identified Proteins

| Identified Proteins                          | Accession Number | Molecular Weight | “Probability” Variance (Variance) | MMP-9 | dFN | FN-9 |
|---------------------------------------------|------------------|------------------|----------------------------------|-------|-----|------|
| Matrix metalloprotease-9 OS-Hc MMP_HUMAN    | OS-HC:MMMP_HUMAN | 78 kDa           | 95% (100%)                       | 274   | 160 | 190  |
| Major vault protein OS-Homo sapiens HVP_HUMAN | OS-HO:MMVP_HUMAN | 59 kDa           | 0% (26%)                         | 169   | 176 | 212  |
| Ig kappa chain V-V region Len OS-KV450_HUMAN | OS-KV:KV450_HUMAN | 13 kDa           | 0% (12%)                         | 150   | 147 | 146  |
| Collagen alpha-1(XII) chain OS-Hi COCA1_HUMAN | OS-HI:COCA1_HUMAN | 333 kDa          | 0% (22%)                         | 59    | 65  | 85   |
| Collagen alpha-3(VII) chain OS-Hi CODA3_HUMAN | OS-HI:CODA3_HUMAN | 344 kDa          | 0% (42%)                         | 87    | 33  | 44   |
| Protein phosphatase 1 regulatory sv/PTP1_HUMAN | OS-PTP1_HUMAN    | 115 kDa          | 0% (20%)                         | 81    | 92  | 94   |
| Probable Xaa-Pro aminopeptidase XPP3_HUMAN   | OS-XPP3_HUMAN    | 57 kDa           | 0% (19%)                         | 69    | 81  | 78   |
| ATP-dependent RNA helicase A (DHX16_HUMAN)  | OS-DHX16_HUMAN   | 141 kDa          | 0% (11%)                         | 67    | 76  | 57   |
| E3 ubiquitin-protein ligase TRI21 ROS2_HUMAN | OS-TRI21_HUMAN   | 54 kDa           | 0% (26%)                         | 86    | 86  | 88   |
| Polyadenylate-binding protein O PABP1_HUMAN | OS-PABP1_HUMAN   | 71 kDa           | 0% (5%)                          | 64    | 55  | 45   |
| Heterogeneous nuclear ribonucleoprotein HNR1_HUMAN | OS-HNR1_HUMAN    | 96 kDa           | 0% (4%)                          | 57    | 49  | 45   |
| Frataxin OS-Homo sapiens GI FINC_HUMAN       | OS-FCFINC_HUMAN  | 263 kDa          | 0% (32%)                         | 58    | 27  | 41   |
| Slycan-9 OS-Homo sapiens GI-IVYHE_HUMAN      | OS-IVYHE_HUMAN   | 227 kDa          | 0% (22%)                         | 55    | 74  | 66   |
| Regulator of nonsense transcript REN1_HUMAN  | OS-REN1_HUMAN    | 124 kDa          | 0% (13%)                         | 49    | 53  | 49   |
| RNA-binding protein FUS OS-Hon FUS_HUMAN     | OS-HON:FUS_HUMAN | 53 kDa           | 0% (4%)                          | 48    | 40  | 30   |
| Flavin-A OS-Homo sapiens GI-FLNA_HUMAN       | OS-FLNA_HUMAN    | 281 kDa          | 0% (14%)                         | 45    | 51  | 40   |
| Multiple Rho domain protein OS-HMPDZ_HUMAN   | OS-HMPDZ_HUMAN   | 222 kDa          | 0% (30%)                         | 43    | 60  | 62   |
| Procollagen-lysine,2-oxoglutarate PLOD3_HUMAN | OS-PLOD3_HUMAN   | 85 kDa           | 95% (140%)                       | 02    | 0   | 5    |

### Images

**A**
- MMP-9, ΔFN, FN

**B**
- Inputs
- v5 IP
- Flag IP

### Graphs

**C**
- PLA of MMP-9 or ΔFN in wt HSF
- PLA of MMP-9 or ΔFN in LH3 KD HSF
MMP-9 Recruitment to the Cell Surface by LH3

induced α-SMA expression can be inhibited by neutralizing anti-TGF-β antibody indicates that MMP-9-mediated differentiation of MRC-5 into α-SMA-expressing myofibroblasts under our culture conditions occurs in large part through the TGF-β pathway. Moreover, abrogation by excess recombinant FN domain of the ability of MMP-9 to induce α-SMA expression in cultured fibroblasts suggests that the FN domain can inhibit MMP-9 activity at the fibroblast cell surface.

LH3 Provides the Docking Mechanism for MMP-9 Cell Surface Association via the FN Domain—CD44 has been shown to be an MMP-9 docking molecule at the surface of TA3 mouse mammary carcinoma, melanoma cells, and normal keratinocytes (17). However, CD44 does not appear to be necessary for MMP-9 recruitment to the fibroblast membrane (data not shown), and recruitment therefore occurs by a CD44-independent mechanism. To identify candidate MMP-9 docking molecules on the fibroblast cell surface, we performed mass spectrometry analysis of an anti-v5 antibody pulldown of MMP-9, FN, and ∆FN cross-linked to MRC-5 cells. MRC-5 cells were incubated with MMP-9, FN, and ∆FN proteins and labeled with Sulfo-SBED Biotin Label Transfer Reagent after which the putative interactions were cross-linked by UV light at 365 nm for 8 min. Anti-v5 antibody was then used for immunoprecipitation from the corresponding cell lysates (Fig. 5 A), and the immunoprecipitates were subjected to shotgun mass spectrometry. Analysis of the pulldown revealed PLOD3_HUMAN, also known as LH3, to be a specific candidate binding partner of MMP-9 and the FN domain (Fig. 5A).

To verify the interaction between MMP-9 and LH3, we incubated MRC-5 cells with recombinant v5-tagged and Sulfo-SBED-labeled MMP-9, FN, or ∆FN for 4 h at 37 °C, cross-linked the interaction, and collected cell lysates to perform anti-v5 and anti-FLAG control antibody immunoprecipitation. We used anti-endogenous LH3 antibody to reveal the interaction. By immunoblot analysis, we could clearly demonstrate that both v5-tagged MMP-9 and the FN domain can immunoprecipitate endogenous LH3, whereas ∆FN cannot (Fig. 5B). Thus, MMP-9 forms a complex with LH3 via its FN domain.

To further explore this interaction in vivo without resorting to cross-linking, we performed PLAs. HSF were treated with v5-tagged MMP-9 or ∆FN overnight at 37 °C and the following day incubated with mouse anti-v5 and rabbit anti-LH3 antibody prior to paraformaldehyde fixation and subsection to proximity ligation (see “Experimental Procedures”). We compared v5-tagged MMP-9 and ∆FN interaction with endogenous LH3 by quantifying the number of events per cell (reflected by fluorescence signals) in WT HSF or in HSF depleted of LH3. We observed a significantly higher number of events in HSF incubated with MMP-9 than in HSF treated with ∆FN (Fig. 5C, left panel), confirming the requirement of the FN domain for interaction with LH3. Moreover, interaction was abrogated in HSF depleted of LH3 as we detected no significant difference between MMP-9 and ∆FN when LH3 was down-regulated (Fig. 5C, right panel). These observations support the notion that LH3 constitutes a hitherto undiscovered MMP-9 docking structure that specifically recognizes its FN domain. It is noteworthy that LH3 was expressed by tumor cell lines that did not recruit MMP-9 (Fig. 6), suggesting that the observed interaction in MRC5 cells may be due to fibroblast-specific post-translational modifications of LH3.

LH3 Down-regulation Decreases MMP-9 Recruitment to MRC-5 and Thus MMP-9/LH3 Interaction—By identifying the interaction between the FN domain of MMP-9 and LH3, we predicted that down-regulation of LH3 in MRC-5 cells would decrease MMP-9 recruitment. We therefore depleted MRC-5 cells of LH3 and compared recruitment of v5-tagged MMP-9 with that in control cells containing scrambled siRNA sequences by anti-v5 antibody Western blot analysis. As expected, LH3 down-regulation in MRC-5 cells decreased MMP-9 recruitment (Fig. 7A).

To provide further evidence that the MMP-9/LH3 interaction at the cell surface was indeed impaired by LH3 down-regulation, we used PLA to compare the interaction between MMP-9 and LH3 in control HSF versus HSF depleted of LH3. PLA revealed a significant decrease in the number of events per cell in LH3-depleted compared with control HSF (Fig. 7B, upper panel). Moreover, immunofluorescence analysis illustrates both that MMP-9/LH3 interaction occurs at the cell surface and that formation of the complex is impaired when LH3 is down-regulated (Fig. 7B, lower panel). Thus, MMP-9 recruitment to the fibroblast cell surface is selectively mediated by LH3.

MMP-9 Is Displaced from MRC-5 Cell Surface by Its FN Domain—We next addressed the possible mechanism whereby incubation with the recombinant FN domain inhibits both MMP-9-induced TGF-β activation and α-SMA expression. To
MMP-9 Recruitment to the Cell Surface by LH3

A

MMP-9

Recruitment

Adjusted density ×1000

ctl MRC-5

LH3 KD MRC-5

B

PLA of MMP-9/LH3 interaction

nb of events per cell

HSF

LH3 KD HSF

C

PLA of MMP-9 displacement by the FN domain

nb of events per cell

MMP-9 only

FN only

MMP-9+FN 1:1

MMP-9+FN 1:2

MMP-9+FN 1:10

α-v5

α-LH3
do so, we asked whether the FN domain alone might compete with MMP-9 for docking to the fibroblast cell surface and impair MMP-9/LH3 complex formation by displacing MMP-9 from the cell membrane. MRC-5 fibroblasts were incubated with v5-tagged MMP-9 in the presence of increasing concentrations of the FN domain (MMP-9:FN ratios of 1:1, 1:2, and 1:10 or molar ratios of 1:3.4, 1:6.8, and 1:34) after which MMP-9/LH3 interaction was assessed by PLA using mouse anti-MMP-9 antibody, which does not recognize the FN domain, and rabbit anti-LH3 antibody. We observed an increase in the number of fluorescence signals in the cells treated with MMP-9 only compared with cells treated with the FN domain only, confirming that the MMP-9 antibody does not recognize the FN domain (Fig. 7). Moreover, we noted a strong decrease of the MMP-9/LH3 interaction in the presence of a 3.4 molar excess of FN. Thus, recombinant FN domain prevents LH3-dependent MMP-9 anchoring to the MRC-5 cell surface and provides a mechanism of inhibition of MMP-9-mediated TGF-β activation and fibroblast differentiation.

Finally, we assessed α-SMA induction in MRC5 cells depleted of LH3 in response to recombinant MMP-9. Expression of α-SMA in these cells was not enhanced by addition of recombinant MMP-9 to the cell culture medium (Fig. 8). However, induction of α-SMA was rescued by addition of active TGF-β in the presence or absence of MMP-9. These observations support the notion that recruitment by LH3 provides a mechanism for deployment of MMP-9 catalytic activity at the fibroblast cell surface that promotes TGF-β activation and the corresponding enhancement of α-SMA expression.

Discussion

MMP-9 can be recruited to the surface of diverse cell types where it may play an important role in regulating growth factor activation, receptor processing, and pericellular matrix turnover, all of which are highly relevant to tissue remodeling in both physiological and tumor-associated contexts. Thus far, the hyaluronan receptor CD44 has been shown to provide a mechanism for inhibition of MMP-9-mediated TGF-β activation and fibroblast differentiation.

Selective targeting of individual MMPs has been a major hurdle toward therapeutic strategies aimed at blocking MMP-dependent tumor progression as most compounds with potent inhibitory properties are non-selective and tend to block all or nearly all MMP activity with adverse consequences (28, 29). Nevertheless, the continued search for selective means to block single MMPs or subsets thereof has identified potentially promising avenues as illustrated by chemical compounds that target the HEX domain of MMP-9 and that inhibit tumor cell migration and proliferation by abrogating MMP-9 homodimerization (30, 31). An alternative approach may be to target structures that are unique to defined MMPs provided they are shown to play a functionally relevant role in determining MMP localization and activity. The FN domain appears particularly attractive in light of our present observations as, in addition to constituting part of only two MMPs, its delivery in recombinant form may provide selective inhibition of the effect of only this subset of MMPs on fibroblast functions that are highly relevant to tumor progression. Enhanced selectivity of MMP inhibitors has already been achieved by taking advantage of differences in secondary substrate binding sites or exosites within the MMP family (32). Thus, a triple helical peptide that incorporates an FN type II-like motif-binding sequence selectively inhibits MMP-9 type V collagen-specific activity. Similarly, FN type II motif-mediated interaction with LH3 provides a targetable event with potentially beneficial consequences.

Lysyl hydroxylase 3 is a multifunctional protein that localizes to the endoplasmic reticulum but is also secreted into the extracellular space and is associated with collagenous proteins on the cell surface (21). Its principal function resides in lysyl hydroxy-
lase, galactosyltransferase, and glucosyltransferase activities for which sequential deployment is required to generate hydroxylysine and its glycosylated forms (33). More recent studies suggest that deficiency of LH3 glycosyltransferase activity in the extracellular space causes growth arrest, indicating that LH3 glycosyltransferase activity may be important for cell growth and viability (34). Whether these functions may affect MMP-9 activity and vice versa remain to be explored.

The observation that LH3 expressed in a variety of tumor cell types fails to recruit MMP-9 to their cell surface may have several explanations. One possibility is that LH3 undergoes post-translational modifications in fibroblasts but not in tumor cells that enable MMP-9 FN domain recognition. An analogous situation has been observed regarding CD44 recruitment of MMP-9 in selected tumor cells and keratinocytes (18). An alternative possibility is that glycosyltransferase properties of LH3 modify collagenous proteins with which it interacts on the fibroblast cell surface, creating a molecular complex that helps recruit MMP-9. In either case, our observations suggest that at the very least LH3 may provide an important MMP-9 docking mechanism to the fibroblast cell surface that, along with the corresponding cell surface-localized MMP-9 catalytic activity, can be blocked by recombinant FN domain.

Our observation that MMP-9-induced TGF-β activation promotes α-SMA expression in fibroblasts is consistent with a function that supports tumor progression (2, 35). Although the role of cancer-associated fibroblasts in tumor progression is multifaceted as they can inhibit as well as promote malignant growth depending on their activation state and secretion repertoire (36), myofibroblasts are generally believed to support tumor progression by promoting cancer cell survival proliferation and invasiveness. Targeting fibroblasts is thought to be a promising strategy in cancer treatment (37) because they are genetically stable, which reduces the likelihood of drug resistance, and because they are responsible for ECM properties that hamper diffusion of anticancer agents through solid tumors (36). As selective MMP inhibitors are still scarce (28, 29), recombinant FN may provide an attractive reagent for the blockade of a candidate mechanism of MMP-9 activation within the stromal

**FIGURE 8. MMP-9 has no effect in α-SMA induction when LH3 is depleted and can be rescued by active TGF-β.** Control (ctl) and LH3-depleted (KD) MRC-5 were incubated for 72 h days with 0.5 μg/ml pro-MMP-9, FN, ΔFN, TGF-β, or pro-MMP-9 with TGF-β (MMP-9:TGF-β). A representative anti-α-SMA antibody immunoblot of equal amounts of control and LH3-depleted MRC-5 cell lysates from three independent experiments (upper panel) is shown. Analysis of α-SMA expression from three independent experiments (lower panel) is shown. Expression quantification was normalized to tubulin (tub). Results represent mean values ± S.E. (error bars). *, p ≤ 0.05; **, p ≤ 0.01.
FIGURE 9. Hypothetical model. A, model 1. Pro-MMP-9 recruitment to the fibroblast cell surface via LH3 activates latent TGF-β and induces α-SMA expression, reflecting myofibroblast differentiation. B, model 2. Recombinant FN domain inhibits both MMP-9-induced TGF-β activation and α-SMA expression in fibroblasts by displacement of MMP-9.
compartment as well as a structural basis for the design of smaller effective MMP-9 inhibitors.

We report a hitherto undiscovered mechanism of MMP-9 recruitment to the surface of fibroblasts. Cell surface activity of MMP-9 has been shown to be important for TGF-β activation whether on the fibroblast surface or in the immediate pericellular fibroblast microenvironment and may play a critical role in fibroblast differentiation into myofibroblasts, providing a mechanism that underlies the constitution of at least a subset of cancer-associated fibroblasts (Fig. 9A). Recombinant FN domain blocks MMP-9-dependent, TGF-β-mediated myofibroblast differentiation and thereby abrogates a potentially important fueling mechanism of tumor progression (Fig. 9B).

Acknowledgments—We thank Manfredo Quadrioni from the Protein Analysis Facility of University of Lausanne for Mass Spectrometry Analysis and all the members of the laboratory for support and helpful discussion. We particularly thank Nils Degrauwe, Giulia Fregni, Carlo Fucaro, Marie-Aude Le Bitoux, Patricia Martin, and Anne Planche Roduit for precious help.

References

1. Pietras, K., and Ostman, A. (2010) Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316, 1324–1331
2. Mueller, M. M., and Fusseneg, N. E. (2004) Friends or foes—bipolar effects of the tumor stroma in cancer. Nat. Rev. Cancer 4, 839–849
3. Bhowmick, N. A., Neilson, E. G., and Moses, H. L. (2004) Stromal fibroblasts in cancer initiation and progression. Nature 432, 332–337
4. Stamenkovic, I. (2000) Matrix metalloproteinases in tumor invasion and metastasis. Sem. Cancer Biol. 10, 415–433
5. Stamenkovic, I. (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J. Pathol. 200, 448–464
6. Coussens, L. M., Tinkle, C. L., Hanahan, D., and Werb, Z. (2000) MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103, 481–490
7. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tazawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2, 737–744
8. Xu, X., Chen, Z., Wang, Y., Yamada, Y., and Steffensen, B. (2005) Functional basis for the overlap in ligand interactions and substrate specificities of matrix metalloproteinases-9 and -2. Biochem. J. 392, 127–134
9. Collier, I. E., Krasnov, P. A., Strongin, A. Y., Birkedal-Hansen, H., and Goldberg, G. I. (1992) Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen-binding domain from human 92-kDa type IV collagenase. J. Biol. Chem. 267, 6776–6781
10. Steffensen, B., Wallon, U. M., and Overall, C. M. (1995) Extracellular matrix binding properties of recombinant fibronectin type II-like modules of human 72-kDa gelatinase/type IV collagenase. High affinity binding to native type I collagen but not native type IV collagen. J. Biol. Chem. 270, 11555–11566
11. Overall, C. M. (2002) Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. Mol. Biotechnol. 22, 51–86
12. Roomi, M. W., Monterrey, J. C., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tazawa, K., Horimoto, A., Ikawa, Y., Ratzkin, B. J., Arakawa, T., and Noda, M. (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. U.S.A. 95, 13221–13226
13. Redondo-Muñoz, J., Ugarbe-Berzal, E., García-Marco, J. A., del Cerro, M. H., Van den Steen, P. E., Opdam, K., and García-Pardo, A. (2008) r4β1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 bioavailability via inhibition and binding to cargo receptors. J. Biol. Chem. 283, 18626–18637
14. Takahashi, C., Sheng, Z., Horan, T. P., Kitayama, H., Maki, M., Hitomi, K., Kitaura, Y., Takai, S., Sasahara, R. M., Horimoto, A., Ikawa, Y., Ratzkin, B. J., Arakawa, T., and Noda, M. (1998) Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. U.S.A. 95, 13221–13226
15. Redondo-Muñoz, J., Ugarbe-Berzal, E., García-Marco, J. A., del Cerro, M. H., Van den Steen, P. E., Opdam, K., and García-Pardo, A. (2008) α4β1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells. Blood 112, 169–178
16. Behrendt, N. (2004) The urokinase receptor (uPAR) and the uPAR-associated protein (uPARP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol. Chem. 385, 103–136
17. Brinkerhoff, C. E., and Matrisian, L. M. (2002) Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 3, 207–214
18. Coussens, L. M., Fingleton, B., and Matrisian, L. M. (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387–2392
19. Dufour, A., Sampson, N. S., Li, J., Kuscu, C., Rizzo, R. C., Deleon, J. L., Zhi, J., Jaber, N., Liu, E., Zucker, S., and Cao, J. (2011) Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 71, 4977–4988
20. Dufour, A., Zucker, S., Sampson, N. S., Kuscu, C., and Cao, J. (2010) Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides. J. Biol. Chem. 285, 35945–35956
21. Lauer-Fields, J. L., Whitehead, J. K., Li, S., Hammer, R. P., Brew, K., and Fields, G. B. (2008) Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J. Biol. Chem. 283, 20087–20095
22. Myllylä, R., Wang, C., Heikkinen, J., Jaber, N., Lampela, O., Risteli, M., Ruotsalainen, H., Salo, A., and Sipilä, I. (2007) Expanding the lysyl hydrox-
MMP-9 Recruitment to the Cell Surface by LH3

ylase toolbox: new insights into the localization and activities of lysyl hydroxylase 3 (LH3). J. Cell. Physiol. 212, 323–329
34. Wang, C., Kovanen, V., Raudasoja, P., Eskelinen, S., Pospiech, H., and Myllylä, R. (2009) The glycosyltransferase activities of lysyl hydroxylase 3 (LH3) in the extracellular space are important for cell growth and viability. J. Cell. Mol. Med. 13, 508–521
35. Kalluri, R., and Zeisberg, M. (2006) Fibroblasts in cancer. Nat. Rev. Cancer 6, 392–401
36. Cirri, P., and Chiarugi, P. (2012) Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 31, 195–208
37. Loeffler, M., Krüger, J. A., Niethammer, A. G., and Reisfeld, R. A. (2006) Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Investig. 116, 1955–1962